SCHEMBL8129302

SCHEMBL8129302

CNS(=O)(=O)Cc1ccc(C#N)cc1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 2/20 0.57
MAPT P10636 2/20 0.54
CYP19A1 P11511 2/20 0.50
CYP2A6 P11509 2/20 0.50
SAE1 Q9UBE0 1/20 0.46
UBA2 Q9UBT2 1/20 0.46
BCHE P06276 1/20 0.44
ACHE P22303 1/20 0.44
CA1 P00915 3/20 0.43
CA2 P00918 3/20 0.43
ALDH1A1 P00352 3/20 0.42
NAMPT P43490 1/20 0.42
CA12 O43570 2/20 0.42
CA9 Q16790 2/20 0.42
CA4 P22748 1/20 0.42
PARP14 Q460N5 1/20 0.41
ALKBH5 Q6P6C2 1/20 0.40
LSS P48449 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18571240 0.81 CA1 (0.42) LOXL2MAPTCA1CA2CA12
SCHEMBL16000123 0.80 MAPT (0.50) LOXL2MAPTCYP19A1CYP2A6BCHE
SCHEMBL19708884 0.80 CYP19A1 (0.50) LOXL2MAPTCYP19A1CYP2A6BCHE
SCHEMBL5421553 0.80 MAPT (0.58) LOXL2MAPTCYP19A1CYP2A6SAE1
SCHEMBL2717669 0.79 MAPT (0.61) LOXL2MAPTCYP19A1CYP2A6SAE1
SCHEMBL4636453 0.79 GLA (0.49) MAPTCYP19A1ALDH1A1PARP14
SCHEMBL17227603 0.78 CYP2A6 (0.57) LOXL2MAPTCYP19A1CYP2A6SAE1
SCHEMBL9046172 0.78 GAA (0.48) CA1CA2ALDH1A1CA12CA9
SCHEMBL8261072 0.78 HPGD (0.48) CYP2A6CA1CA2ALKBH5
SCHEMBL7879672 0.76 ALDH1A1 (0.51) LOXL2MAPTCYP19A1CYP2A6CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9199959-B2 HIV replication inhibitor SHIONOGI & CO., LTD. (JP) 2015-12-01 US disclosed
US-20140249306-A1 HIV REPLICATION INHIBITOR SHIONOGI & CO., LTD. (JP) 2014-09-04 US disclosed
US-20120165309-A1 HETERO RING DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-28 US disclosed
EP-2397479-A1 HETERO RING DERIVATIVE Astellas Pharma Inc. (JP) 2011-12-21 EP disclosed
WO-2010092962-A1 HETERO RING DERIVATIVE アステラス製薬株式会社 (JP) 2010-08-19 WO disclosed
US-6114390-A AN ARGININAMIDE OR ORNITHINAMIDE COMPOUND AS TREATING MEMORY LOSS, MIGRAINE, SLEEP DISORDERS, PAIN, CARDIOVASCULAR DISEASES, SUBARACHNOIDAL BLEEDING, VASCULAR-HYPERTROPHIC CHANGES, CEREBRAL AND CORONARY VASOSPASMS KARL THOMAE GMBH (DE) 2000-09-05 US disclosed
EP-0885186-A1 AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND PROCESSES FOR PREPARING THEM Dr. Karl Thomae GmbH (DE) 1998-12-23 EP disclosed
WO-1997019911-A1 AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND PROCESSES FOR PREPARING THEM DR. KARL THOMAE GMBH (DE) 1997-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165309-A1 HETERO RING DERIVATIVE IL2, PIK3R2, IL2RA LOXL2 304/4885MAPT 3968/4885CYP19A1 1511/4885
US-20140249306-A1 HIV REPLICATION INHIBITOR SSU72, RTF2, ZC3HAV1 LOXL2 3884/4885MAPT 3377/4885CYP19A1 1841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.